Opinion

Video

EHA 2024: Teclistimab in High-Risk Relapsed/Refractory Multiple Myeloma

Author(s):

Joseph Mikhael, MD

Dr. Mikhael discusses the safety and usefulness of tesclistimab in patients with high-risk refractory multiple myeloma.

Video content above is prompted by the following question:

  1. Discuss the data presented at EHA 2024 on the efficacy and safety of teclistimab in patients with relapsed/refractory multiple myeloma (RRMM) with high-risk features: a subgroup analysis of the phase 1/2 MajesTEC-1 study. (Abstract)
    1. What was the objective of the subgroup analysis of this study?
    2. How was this study designed/what methodology was used?
    3. What results were presented?
      1. N=165
    4. N=24 aged ≥75 years
    5. N=20 ISS stage III
    6. N=38 high-risk cytogenetics
    7. N=28 extramedullary disease
    8. N=18 bone marrow plasma cells
    9. N=50 penta-drug refractory
      1. Median follow up ~30 months across subgroups
      2. Objective Response Rate (ORR)
      3. Median duration of response (mDOR)
      4. Safety
Related Videos
Hans Lee, MD
1 KOL is featured in this series.
Don M. Benson, MD, PhD, James Cancer Hospital
1 KOL is featured in this series.
1 KOL is featured in this series.
Hans Lee, MD
Matias Sanchez, MD
Matias Sanchez, MD
Related Content
Highlights from SLEEP 2024
December 18th 2024

ICYMI: Highlights From SLEEP 2024

Kyle Munz
Check out our top 5 most-viewed pieces of coverage from the 2024 SLEEP meeting.
ICYMI: Highlights From IMS 2024
December 17th 2024

ICYMI: Highlights From IMS 2024

Maggie L. Shaw
The expert knowledge presented at this year’s International Myeloma Society (IMS) annual meeting focused on minimal residual disease testing and status, defining and treating high-risk disease, CEPHEUS trial findings, and an investigational off-the-shelf chimeric antigen receptor T-cell therapy.
ICYMI: Highlights From ACTRIMS 2024
December 12th 2024

ICYMI: Highlights From ACTRIMS 2024

Kyle Munz
Read about the diverse array of research presented at this year's meeting, including novel technological advancements and insights into disease progression in multiple sclerosis (MS).
EHA Highlights thumbnail
December 5th 2024

ICYMI: Highlights From EHA 2024

Maggie L. Shaw
Presentations at the European Hematology Association (EHA) 2024 Congress were encouraging for their data on innovations within the hematology/oncology space that are reshaping treatment outcomes.
Guidelines | Image Credit: © momius-stock.adobe.com
November 26th 2024

NCCN Guidelines Prioritize Quad Therapy in Multiple Myeloma

Maggie L. Shaw
In the most recent update to the National Comprehensive Cancer Network (NCCN) guidelines for treating patients who have multiple myeloma, a quadruplet regimen became the preferred first-line treatment option for transplant-eligible and -ineligible patients.
Don M. Benson, MD, PhD, James Cancer Hospital
November 22nd 2024

Balancing Life and Myeloma: A Patient-Centered Approach

Maggie L. Shaw
In this second part of our discussion with Don M. Benson, MD, PhD, from our recent Institute for Value-Based Medicine® event in Cleveland, Ohio, he explains how his ultimate goal for his patients is for them to live as long and as well as possible.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo